Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00595491 · ClinicalTrials.gov registry record · Phase 1

Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation

A Phase 1 study of Asthma, sponsored by Benjamin Medoff.

Recruiting
Registry status
Phase 1
Development phase
313
Enrollment target
1
Study location

NCT00595491 is a Phase 1 study of Asthma that is actively recruiting participants, run by Benjamin Medoff. The registered enrollment target is 313 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00595491, a Phase 1 study of Asthma, is actively recruiting participants, sponsored by Benjamin Medoff.

RECRUITING
Registry status
Phase 1
Development phase
313 participants
Enrollment target
1
Study location

Study Summary

Asthma is a heterogeneous disorder in which multiple potential inflammatory pathways contribute to airway obstruction. The biological basis for airway inflammation is the subject of intensive investigation. This work is designed to identify airway factors that are responsible for recruiting cells and associate their airway presence with atopy and asthma.

Conditions Studied

Interventions

  • BIOLOGICAL Bronchoscopy, Segmental Allergen Challenge, and Broncheoalveolar Lavage

Study Locations (1)

Massachusetts

  • Massachusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 313 participants
Start Date 2008-01
Est. Completion 2029-01-31
Phase Phase 1

Sponsor

Benjamin Medoff

1 total trials

What the Registry Record Tells You About NCT00595491

The ClinicalTrials.gov registry entry for NCT00595491 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 313 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (80% lower). The listed sponsor is Benjamin Medoff, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 1 intervention - of which Bronchoscopy, Segmental Allergen Challenge, and Broncheoalveolar Lavage is the first listed.

NCT00595491 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT00595491 about?

NCT00595491 is a clinical study titled "Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation". Asthma is a heterogeneous disorder in which multiple potential inflammatory pathways contribute to airway obstruction. The biological basis for airway inflammation is the subject of intensive investigation. This work is designed to identify airway factors that are responsible for recruiting cells an...

What is the current status of trial NCT00595491?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 313 participants. The study started on 2008-01. Estimated completion is 2029-01-31.

What conditions does trial NCT00595491 study?

This clinical trial studies the following conditions: Asthma.

What interventions are being tested in trial NCT00595491?

The interventions under investigation include: Bronchoscopy, Segmental Allergen Challenge, and Broncheoalveolar Lavage (BIOLOGICAL).

Who is sponsoring clinical trial NCT00595491?

This trial is sponsored by Benjamin Medoff, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00595491 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Asthma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.